What is Axsome?
Axsome Therapeutics, Inc. operates as a high-growth biopharmaceutical enterprise dedicated to the discovery and development of innovative therapies for central nervous system conditions. The company distinguishes itself through a focus on therapeutic options that utilize novel mechanisms of action, effectively targeting patient populations with limited existing treatment alternatives. By prioritizing rigorous clinical development and patient-centric outcomes, Axsome has established a formidable presence in the CNS market, positioning itself as a key player in the evolution of neurological and psychiatric care. Their business model integrates advanced research capabilities with strategic commercialization efforts, ensuring that their pipeline of products is well-positioned to address the complexities of modern medicine.
How much funding has Axsome raised?
Axsome has raised a total of $650.5M across 7 funding rounds:
Debt
$3.7M
Debt
$2M
Debt
$1.3M
Debt
$2.5M
Stock Offering
$51M
Debt
$20M
Debt
$570M
Debt (2013): $3.7M, investors not publicly disclosed
Debt (2014): $2M, investors not publicly disclosed
Debt (2014): $1.3M, investors not publicly disclosed
Debt (2015): $2.5M, investors not publicly disclosed
Stock Issuance/Offering (2015): $51M, investors not publicly disclosed
Debt (2016): $20M with participation from Silicon Valley Bank
Debt (2025): $570M led by Blackstone
Key Investors in Axsome
Blackstone
Blackstone is a global investment firm that focuses on building and managing diversified asset portfolios across private equity, real estate, credit and strategic alternatives.
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, private wealth management, brokerage and investment services, and business valuation services.
Undisclosed Investors
What's next for Axsome?
Looking ahead, the strategic deployment of the $570M investment will likely focus on scaling the company's clinical trial infrastructure and expanding its commercial footprint. With a proven track record of securing diverse financing instruments, Axsome is well-equipped to navigate the capital-intensive nature of drug development. The firm's future growth will be defined by its ability to translate its research-heavy pipeline into market-ready solutions, thereby enhancing its competitive advantage in the CNS sector. Investors and stakeholders will be closely monitoring the company's progress in achieving key regulatory milestones and its capacity to maintain a sustainable growth trajectory in an increasingly competitive biopharmaceutical environment.
See full Axsome company page
